Vaccine Inequity
www.sciencemag.org
Science | AAAS
www.sciencemag.org
-
Take 30 seconds to register your free account to access deals, post topics, and view exclusive content! Register TodayJoin the largest Oakley Forum on the web!
🦘Cacatman's Personal Coronavirus COVID-19 Update Thread
- Thread starter cacatman
- Start date
Covid: Zero daily deaths announced in UK for first time
The latest figures come amid concern over a recent small rise in cases linked to the Indian variant.
www.bbc.com
First time since March 2020. Delta variant on the increase though.
Complications - Neurological issues Post COVID-19
- Loss of gray matter in survivors (study from 782 volunteers)
- serious infections of COVID-19 may damage the brain leading to long-term complications such as stroke or dementia-like symptoms. The authors noted that more data is needed to adequately assess the effects of COVID-19 on brain health, though.
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
Our study provides evidence for substantial neurological and psychiatric morbidity in the 6 months after COVID-19 infection. Risks were greatest in, but not limited to, patients who had severe COVID-19. This information could help in service planning and identification of research priorities...www.thelancet.com
Testing - PCR False Negative/False Positives
Our findings come mainly from 38 studies that provided results based on the time since people first noticed symptoms.
Antibody tests one week after first symptoms only detected 30% of people who had COVID-19. Accuracy increased in week 2 with 70% detected, and was highest in week 3 (more than 90% detected). Little evidence was available after week 3. Tests gave false positive results in 2% of those without COVID-19.
Results from IgG/IgM tests three weeks after symptoms started suggested that if 1000 people had antibody tests, and 50 (5%) of them really had COVID-19 (as we might expect in a national screening survey):
- 58 people would test positive for COVID-19. Of these, 12 people (21%) would not have COVID-19 (false positive result).
- 942 people would test negative for COVID-19. Of these, 4 people (0.4%) would actually have COVID-19 (false negative result).
If we tested 1000 healthcare workers (in a high-risk setting) who had had symptoms, and 500 (50%) of them really had COVID-19:
- 464 people would test positive for COVID-19. Of these, 7 people (2%) would not have COVID-19 (false positive result).
- 537 people would test negative for COVID-19. Of these, 43 (8%) would actually have COVID-19 (false negative result).
View attachment 878596
Testing for SARS-CoV-2 antibodies
### What you need to know As the covid-19 pandemic has unfolded, interest has grown in antibody testing as a way to measure how far the infection has spread and to identify individuals who may be immune.1 Testing also has a clinical role, given the varying symptoms of covid-19 and false...www.bmj.com
Manimal
Oakley Expert
- 151
- 703
Dr. Michael Yeadon – Full Interview | The Awakening 3
This is a must-watch interview! If you’ve ever had any doubts, or needed the right information to put everything into proper context, this is the interview! We sat down with former Pfizer Vice President and Chief of Sci
brandnewtube.com
Manimal
Oakley Expert
- 151
- 703
Two-Tier Society, Vaccine passports & Psychological Manipulation
Support my work here: https://computingforever.com/donate/ Support my work on Subscribe Star: https://www.subscribestar.com/dave-cullen Follow me on Bitchute: https://www.bitchute.com/channel/hybM74uIHJKf/ Buy How is This a Thing Mugs here: https://teespring.com/stores/computing-forever-store...
www.bitchute.com
Treatment - Remdesivir, Dexamethasone Studies
Remdesivir (IV only) reduced hospital stay, but no proven improvement in mortality rate.
Dexamethasone was the first drug proven to save lives 6 mg orally/IV. But only patients on O2 (RECOVERY Trial) - given for 10 days. CRP and ferritin improves. LDH decreases. D-dimer decreases. Not necessary to taper off Dex at 10 days. Could make case to continue dexamethasone.
Acid base status/na/k/cl/hco3/BUN/Cr/Glucose - Check carefully
Hyperventilating in ICU may cause hypernatraemia due to dehydration
Plasma has been used but no controlled trials.
Coronavirus breakthrough: dexamethasone is first drug shown to save lives
In a large trial, a cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19.
www.nature.com
FDA clears remdesivir for emergency use in treating severely ill COVID-19 patients
The drug is not a cure, but has been shown to help the sickest COVID-19 patients.
www.nbcnews.com
Dexamethasone, a corticosteroid, is the only drug found to have a mortality benefit in SARS-CoV-2 infection in a controlled trial. However, several forms of corticosteroids have shown some degree of clinical benefit in COVID. In some patients who progress to severe COVID-19 disease, it appears that the host immune response may lead to lung injury and multisystem organ dysfunction (Huang, January 2020; Moore, May 2020). Multiple studies on the use of corticosteroids in severe COVID-19 are underway to determine how they may mitigate pathology resulting from hyper-inflammation.
Corticosteroids have been studied via many routes of dosing, most recently the inhaled route, with a study of inhaled budesonide that has shown reduction in hospitalization among patients on inhaled budesonide.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum...www.thelancet.comAAAS
science.sciencemag.org
Immunomodulators
www.idsociety.org
J & J (Johnson & Johnson) Vaccine Paused
Six cases of cerebral venous sinus thrombosis (CVST) combined with thrombocytopenia were reported in the U.S., all among women ages 18-48, and all within 6-13 days, with a median of 9 days following vaccination with the Johnson & Johnson vaccine, the agencies reported in a statement.
With approximately 6.8 million doses administered in the U.S., it suggests a one-in-a-million risk. Johnson & Johnson said it was halting the product's distribution in Europe, reportedly taking officials there by surprise.
J&J COVID Vaccine Pause Not an Overreaction, Officials Say
CDC, FDA cite need to educate clinicians on rare adverse event
www.medpagetoday.com
Out of the over 12 million people who have received the vaccine, there are roughly 100 cases that may be associated with the syndrome. Guillain-Barré syndrome (GBS) is a rare neurological disorder in which the body’s immune system attacks the network of nerves located outside of the brain and spinal cord. Cases can range from mild, with a person experiencing brief periods of weakness, to serious cases that result in paralysis that leaves the person unable to breathe independently, sometimes resulting in death.
Guillain-Barré syndrome: Why experts are still “confident” in J&J
The chances of developing Guillain-Barré Syndrome (GBS) the Johnson & Johnson Covid-19 vaccine are small; what you need to knowwww.inverse.com
Data now published in a major journal show that the Johnson & Johnson COVID-19 vaccine generated strong activity against SARS-CoV-2 for at least 8 months, including against variants of concern.
J&J vaccine provides durable immunity, including against variants
Data now published in a major journal show that the Johnson & Johnson COVID-19 vaccine generated strong activity against SARS-CoV-2 for at least 8 months, including against variants of concern.The results were published in a correspondence today in The New England Journal of Medicine, several...www.healio.com
J&J vaccine protects against delta variant for at least 8 months, studies find
Data from two preprint studies showed that Johnson & Johnson’s one-dose COVID-19 vaccine generates “strong, persistent activity” against SARS-CoV-2 variants of concern, including the rapidly spreading delta variant, the company reported.The findings were reported in a press release and the...
J & J (Johnson & Johnson) Vaccine Paused
Six cases of cerebral venous sinus thrombosis (CVST) combined with thrombocytopenia were reported in the U.S., all among women ages 18-48, and all within 6-13 days, with a median of 9 days following vaccination with the Johnson & Johnson vaccine, the agencies reported in a statement.
With approximately 6.8 million doses administered in the U.S., it suggests a one-in-a-million risk. Johnson & Johnson said it was halting the product's distribution in Europe, reportedly taking officials there by surprise.
J&J COVID Vaccine Pause Not an Overreaction, Officials Say
CDC, FDA cite need to educate clinicians on rare adverse event
www.medpagetoday.com
Out of the over 12 million people who have received the vaccine, there are roughly 100 cases that may be associated with the syndrome. Guillain-Barré syndrome (GBS) is a rare neurological disorder in which the body’s immune system attacks the network of nerves located outside of the brain and spinal cord. Cases can range from mild, with a person experiencing brief periods of weakness, to serious cases that result in paralysis that leaves the person unable to breathe independently, sometimes resulting in death.
Guillain-Barré syndrome: Why experts are still “confident” in J&J
The chances of developing Guillain-Barré Syndrome (GBS) the Johnson & Johnson Covid-19 vaccine are small; what you need to know
Data now published in a major journal show that the Johnson & Johnson COVID-19 vaccine generated strong activity against SARS-CoV-2 for at least 8 months, including against variants of concern.
J&J vaccine provides durable immunity, including against variants
Data now published in a major journal show that the Johnson & Johnson COVID-19 vaccine generated strong activity against SARS-CoV-2 for at least 8 months, including against variants of concern.The results were published in a correspondence today in The New England Journal of Medicine, several...
J&J vaccine protects against delta variant for at least 8 months, studies find
Data from two preprint studies showed that Johnson & Johnson’s one-dose COVID-19 vaccine generates “strong, persistent activity” against SARS-CoV-2 variants of concern, including the rapidly spreading delta variant, the company reported.The findings were reported in a press release and the...
EMA’s safety committee (PRAC) has recommended that people who have previously had capillary leak syndrome must not be vaccinated with COVID-19 Vaccine Janssen.
